Planview Blog

Your path to business agility

Product Portfolio Management, Project Portfolio Management, Strategic Planning

Manage risks, but don’t eliminate them – Enrich Consulting

Published By Dr. Richard Sonnenblick

Wait, what? When is it bad to eliminate risks? Many companies we speak with are keen to score their portfolio of initiatives across a number of dimensions like:

  • Strategic fit
  • Market value
  • Development cost
  • Technical risk
  • Commercial risk

So far so good. The process goes awry when teams, seduced by the idea of simplicity, distill all the dimensions into a single score for each project. High strategic fit and market value are “good” and increase the score, while high cost and risk are “bad” and reduce the score.

And therein lies the problem. This single score approach will always reward low-cost, low-risk projects. Likely outcomes of prioritizing by this single score include:

  • A low-risk or no-risk portfolio that includes only product line extensions and incremental product improvements
  • A portfolio that funds late-stage partnerships that require minimal cash outlays and hold minimal risk but require high-royalty payouts, and thus do little to increase company operating margins.
  • A portfolio that deprioritizes early stage and research initiatives that have higher risks and require longer-term investment, but could yield significant returns over the long run.
  • A company opts to buy back their public shares rather than increase investment in higher risk initiatives (US corporate stock buybacks since the beginning of the year have totaled more than a trillion dollars).

When companies value stability over innovation, some risks increase: they risk slowly losing market share and fading into the background of their industry. So what do we do? The solution lies in the understanding that effective R&D governance cannot, and should not, distill projects into a single number.

The right number of high-risk projects in your portfolio is probably not zero. The exact number will depend on your corporate goals, risk tolerance, and financial reserves. Here are a few different ways to assess and communicate risk in your portfolio:

Risk vs. Reward

Rather than bury risk in an overall project score, construct a time-tested risk vs. reward chart to highlight the trade-offs (or lack thereof) between project risk and project value. Management may be surprised to see how many (few?) risky projects populate the portfolio.

Two score categories come together in this risk reward chart. Median lines segment the initiatives into relative quadrants of high/low-risk and value.

If your firm tends to be risk averse, you might also consider recasting risk in the language of innovation. Rather than a risk score, assess technology readiness, or initiative innovation levels.

Project Pipeline

You can also look at the balance of high- and low-risk initiatives in the portfolio. Are your high-risk projects all concentrated in one division or market segment? Given the attrition you expect in your development lifecycle, is the balance of early- to late-stage initiatives appropriate? Are these allocations by design, or happenstance?

Overlaying risk scores on this pipeline view reveals moderate-to-high risk scores on all Immunology initiatives.

Portfolio Revenue with Uncertainty

Bubble charts are eye-catching, but they don’t address key questions of sufficiency: Do you have a sufficiently ambitious portfolio to meet your medium- and long-term goals? For that, you need to forecast project returns across the portfolio to understand how many high-risk high-return initiatives must be funded to increase the chances of meeting portfolio goals.

Revenue forecasts for two alternative portfolio investment plans, shown with uncertainty bands.

With the right financial mechanics, you can forecast portfolio revenue while accounting for development attrition and commercial uncertainties. You may come to the conclusion that even if everything goes your way, reaching revenue goals is unlikely (an uncomfortable, yet important, realization).

Balancing Value and Competing Objectives

You can use charts like this prioritization dashboard to illustrate portfolio value (in the frontier on the right) and balance (in the bar charts on the left for division, stage, and revenue over time, respectively). You can learn more about this type of prioritization here.

Interactive dashboards such as this one help clarify the portfolio’s ability to meet divergent objectives.

Operational Risks

Finally, you can use charts like this flag chart to identify the mix of high and low risk projects in terms of upcoming milestones or reviews. There are many charts that can be improved by overlaying some aspect of project risk.

A more operational view of risks assesses risk of projects with upcoming milestones.

Eyes-Wide-Open: Risks Ahead

By now it’s clear I’m not suggesting we should ignore risks; It is critically important to assess project risk across the portfolio. Risk assessment allows teams to identify the highest risks affecting the portfolio and focus their experience and talent on risk mitigation. But we need to differentiate between risks that should be mitigated (often with mitigation efforts that have a very high ROI), and risks that can only be resolved through the normal course of development.

The methods I’ve discussed above vary in sophistication from Monte Carlo methods simulating thousands of financial outcomes for each project to simple project inventories, but skew towards the simple rather than the complex. Adding methodological sophistication isn’t always the solution: Brick and bar views are transparent, simple to explain, and are more likely to spur important conversations about portfolio value and balance among your decision makers. In the end, those conversations will be more important than the sophistication of the analytic methods you employ.

How do you measure and account for risk in your product portfolio? Does your organization recognize and fund more innovative, less-certain initiatives to ensure a long-term future?

Related Posts

Written by Dr. Richard Sonnenblick Chief Data Scientist

Dr. Sonnenblick, Planview’s Chief Data Scientist, holds years of experience working with some of the largest pharmaceutical and life sciences companies in the world. Through this in-depth study and application, he has successfully formulated insightful prioritization and portfolio review processes, scoring systems, and financial valuation and forecasting methods for enhancing both product forecasting and portfolio analysis. Dr. Sonnenblick holds a Ph.D. and MS from Carnegie Mellon University in Engineering and Public Policy and a BA in Physics from the University of California, Santa Cruz.